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Objective: The aim of this study was to evaluate which clinical variables might influence the antiobsessional responses to proser-
otonergic drugs in a sample of patients with obsessive-compulsive disorder (OCD).
Methods: Two hundred forty-nine patients with DSM-IV OCD under-gone mean 13-month treatments with selective serotonin 
reuptake inhibitors. According to the treatment response, defined as a reductions of the Yale-Brown Obsessive Compulsive 
Scale (Y-BOCS) total score ≥35%, patients were divided into two groups.
Results: One hundred fourteen patients responded to the treatment and the other one hundred thirty five patients did not. 
Responders had a significant long duration of medication in YUMC OCD clinic, short total duration of past treatment in other 
institutes, and higher frequency of drug naïve cases and lower baseline Y-BOCS scores.
Conclusion: The pre-treatment factors including total duration of past treatment, drug naïve or not, baseline OCD symptoms 
and the factor of duration of the treatment may influence drug treatment response in OCD patients. 
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INTRODUCTION
Obsessive-compulsive disorder (OCD) is a mental dis-
order consisting of repetitive thoughts and compulsions. 
Recently, selective serotonin reuptake inhibitors (SSRI) 
have been used to improve the prognosis for OCD. 
However, 40-60% of OCD patients do not respond to 
SSRIs.1-4) Research about clinical predictors, including 
clinical and demographic factors, has been conducted to 
develop treatment guidelines and predict the prognoses of 
OCD patients who show resistance to this kind of 
treatment. Several of the major prognostic factors were 
age at onset,5) presence of tics,6,7) social phobia,8) person-
ality disorders,9-11) hoarding,12,13) other types of OCD,14) 
initial severity of OCD symptoms.3) family history of 
OCD,15) insight,16) sex,17-19) and others. A recent paper20) 
showed the anti-obsessional and clinically predictive ef-
fects of sertraline,21) but no studies have satisfactorily 
identified clinical predictors. Additionally, these studies 
addressed only a few partial factors and did not adequately 
identify the effects of various clinical factors on treatment 
response. Analyses of the effects of clinical and socio-
demographic factors have suggested that information 
about clinical factors collected during initial patient eval-
uations can predict treatment responses and prognoses. 
We conducted a retrospective chart review study to inves-
tigate clinical predictors of responses to treatment with 
SSRIs according to sociodemographic and clinical 
factors.
METHODS
Subjects
This study included 249 patients with OCD who visited 
the YUMC (Yonsei University Medical Center) OCD 
clinic from October 1997 to October 2002. The subjects 
included participants 16-55 years of age who were diag-
nosed with OCD according to the criteria in the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV), and who provided informed consent 
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Table 1. Characteristics of the total sample 
Total (n=246)
Sex
Age
Onset age
Duration of illness (months)
Comorbidity
  Mood disorder
  Personality disorder 
  Anxiety disorder
  Tic disorder
  Somatization disorder
Family History of OCD
Family History of Tic disorder
Poor insight cases
Y-BOCS total baseline score
DOM (months)
DOP(months)
Drug naïve cases
 Male (n=180), Female (n=66)
 30.78 (SD=11.53)
 21.42 (SD=9.69)
102.21 (SD = 82.05)
 65 (26.1%)
 61 (24.5%) 
 39 (15.7%)
 18 (7.2%)
  3 (1.2%)
 30 (12.0%)
 10 (4.0%)
111 (44.6%)
 29.22 (SD=6.93)
 25.09 (SD=23.53)
 18.15 (SD=18.61)
 90 (36.1%)
n, number; R, Response; N, Non-response; Y-BOCS, Yale-Brown 
Obsessive-Compulsive Scale; OCD, Obsessive Compulsive 
Disorder; DOM, Duration of medication in YUMC OCD clinic; DOP, 
Duration of past treatment in other institutes.
for participation in this study. Exclusion criteria were 1) 
women who did not use contraception and had some pos-
sibility of being pregnant; 2) women who were pregnant 
or breast feeding; 3) those with a current or previous or-
ganic, neurological, or substance use disorder; and 4) pa-
tients with abnormal CBC values, urine analysis, liver 
function test, electrolytes, and EKGs. 
Evaluation of Clinical Manifestations
The Yale-Brown Obsessive-Compulsive Scale (Y- 
BOCS)22) has been used to evaluate the severity of symp-
toms of patients with OCD. All patients were observed for 
3-72 months, with an average observation period of 12.9 
months (SD=13.8). 
Pharmacotherapy
OCD symptoms were treated with drugs such as fluox-
etine (40-80 mg/day), sertraline (100-150 mg/day), parox-
etine (40-60 mg/day), and clomipramine (150-300 mg/ 
day). Benzodiazepines (alprazolam, clonazepam, loraze-
pam), mirtazapine, and trazodone were added if necessary 
for treating the OCD symptoms and comorbid disorders of 
each patient. 
Statistical Analysis
Sociodemographic parameters and clinical variables 
were analyzed according to sex and previous responses to 
treatment. Continuous variables were analyzed with 
Student’s t-test, and nominal variables were analyzed with 
chi-square tests. Participants were categorized into two 
groups according to clinical response. Those demonstrat-
ing at least a 35% improvement in scores on the Y-BOCS 
were placed into the responder group, and others were 
placed into the non-responder group. Groups were ana-
lyzed according to sociodemographic and clinical varia-
bles. Logistic regression analysis was performed to inves-
tigate the clinical predictors of drug response. All stat-
istical analyses were conducted using SPSS version 10.0 
(SPSS Inc., Chicago, NJ, USA) for Windows.
RESULTS
Sociodemographic and Clinical Characteristics of 
Subjects (Table 1)
The total sample consisted of 249 participants, includ-
ing 180 males (72%) and 66 females (27%). The average 
age of subjects was 30.78 (SD=11.53) years, the average 
age of onset of OCD was 21.42 (SD=9.69) years, and the 
average duration of OCD was 102.21 (SD=82.05) mon-
ths. The average total score on the total Y-BOS was 29.22 
(SD=6.93); 65 (26.1%) participants suffered from a mood 
disorder, 61 (24.5%) met criteria for a personality dis-
order, 39 (15.7%) had anxiety disorders, 18 (7.2%) had tic 
disorders, and 3 (1.2%) suffered from somatoform 
disorder. Additionally, 30 (12.0%) reported a family his-
tory of OCD, and 10 (4.0%) had a family history of tic 
disorders. 
Differences Between Responder and Non-Responder 
Groups in Terms of Clinical Parameters and 
Sociodemographic Factors (Table 2)
The comparison of the sociodemographic and clinical 
characteristics of responders and non-responders revealed 
significant differences in baseline Y-BOS scores (t=2.245, 
df=164, p=0.016), duration of receiving medication at the 
YUMC OCD clinic (t=3.262, df=163, p=0.001), duration 
of previous treatment at other institutions (t=2.044, 
df=151, p=0.043), and initial drug-naïve status (λ2= 
6.538, df=1, p=0.001). However, no significant differ-
ences between responders and non-responders were ob-
served in terms of sex, age, age at onset, duration of ill-
ness, comorbid disorders, family history of OCD, family 
history of tic disorders, and level of insight.
Clinical Subtypes and Comorbid Disorders of Patients 
with OCD (Table 3)
As noted above, 65 participants had comorbid mood 
disorders (26.1%) such as depression, 39 had anxiety dis-
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Table 2. Characteristics of the sample according to clinical response
R (n= 114) N (n=135) Statistics
Sex
Age
Onset age
Duration of illness (months)
Comorbidity
  Mood disorder
  Personality disorder
  Anxiety disorder
  Tic disorder
  Somatization disorder
Family History of OCD
Family History of Tic disorder
Poor insight cases
Y-BOCS total baseline score*
DOM† (months) 
DOP* (months) 
Drug naïve cases†
M (78), F (36)
 31.46 (12.86)
 22.53 (11.23)
102.48 (78.78)
24
24
21
 7
 1
10
 4
45
27.94 (7.18)
 31.86 (24.66)
 14.19 (15.44)
54
M (102), F (33)
 30.21 (10.36)
20.47 (8.09)
101.98 (85.19)
41
37
18
11
 2
20
 6
66
30.31 (5.21)
 19.38 (22.59)
 21.52 (21.30)
36
λ2=0.959
T=0.689
T=1.361
T=0.040
λ2=2.771
λ2=1.344
λ2=1.206
λ2=0.370,
λ2=0.189
λ2=2.121
λ2=0.140
λ2=2.209
T=2.245
T=3.262
T=2.044
λ2=6.538
p=0.327
p=0.492
p=0.175
p=0.968
p=0.096
p=0.246
p=0.272
p=0.543
p=0.664
p=0.145
p=0.708
p=0.137
p=0.016
p=0.001
p=0.043
p=0.001
R: Response, N: Non-response, n: number, M: male, F: female, Y-BOCS: Yale-Brown Obsessive-Compulsive Scale, OCD: Obsessive Compulsive 
Disorder, DOM: Duration of medication in YUMC OCD clinic, DOP: Duration of past treatment in other institutes. 
*p＜0.05, †p＜ 0.001. 
Table 3. Comorbidity of obsessive compulsive disorder
Disease entities Specific diseases T (%) R (%) N (%)
Mood disorder (n=65)
Anxiety disorder (n=39)
Somatization disorder (n=3)
Personality disorder (n=61)
Child onset diseases (n=22)
Psychotic disorder (n=15)
Others (n=4)
Depression
Dysthymia
Bipolar disorder
Other emotional problem
Panic disorder
Hypochondriasis
Social phobia
GAD
Other anxiety disorder
Somatization disorder
Obsessive compulsive PD
Avoidant PD
Schizoid PD
Borderline PD
Histrionic PD
Antisocial PD
Schizotypal PD
ADHD
Tic disorder
Psychotic disorder NOS
Alcohol dependence
PMS
57 (22.9)
3 (1.2)
3 (1.2)
2 (8)
7 (2.8)
6 (2.4)
15 (6)
3 (1.2)
8 (3.2)
3 (1.2)
30 (12)
15 (6)
3 (1.2)
5 (2)
3 (1.2)
2 (0.8)
3 (1.2)
4 (1.6)
18 (7.2)
15 (6)
3 (1.2)
1 (0.4)
21 (18.4)
2 (1.8)
1 (0.9)
0
4 (3.5)
3 (2.6)
9 (7.8)
3 (2.6)
2 (1.8)
1 (0.9)
10 (8.8)
9 (7.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
7 (6.1)
6 (5.2)
1 (0.9)
0
36 (26.7)
1 (0.7)
2 (1.5)
2 (1.5)
3 (2.2)
3 (2.2)
6 (4.4)
0
6 (4.4)
2 (1.5)
20 (14.8)
6 (4.4)
2 (1.5)
4 (3)
2 (1.5)
1 (0.7)
2 (1.5)
3 (2.2)
11 (8.1)
9 (6.7)
2 (1.5)
1 (0.7)
T: Total, R: Responder, N: Non-responder, n: number, %: Percent, GAD: Generalized anxiety disorder, PD: Personality disorder, ADHD: 
Attention deficit hyperactivities disorder, NOS: Not otherwise specific, PMS: Pre-menstrual syndrome some patients have more than 2 specific 
diseases. 
orders (15.6%), 61 had personality disorders (24.5%), and 
18 had tic disorders (7.2%). No significant difference be-
tween responders and non-responders were observed in 
terms of comorbid disorders. Twenty-four responders met 
criteria for mood disorders (21.0%), 24 for personality 
disorders (21.0%), 21 for anxiety disorders (18.4%), and 
one for somatoform disorder (0.9%). The non-responders 
group included 41 participants with mood disorders 
(30.3%), 37 with personality disorders (27.4%), 12 with 
anxiety disorders (9%), and two with somatoform dis-
order (1.5%). 
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Table 4. Subtypes of Obsessive symptoms according to clinical response
Types T (%) R (%) N (%)
Checking type compulsion
Washing type compulsion 
Pathologic doubt obsession
Symmetry and precision type compulsion
Aggression obsession
Counting type compulsion 
Hoarding type compulsion
Somatization obsession 
Need to ask or confess type compulsion
Sexual obsession
Need for symmetry obsession
Contamination obsession
Others
Totals
 60 (24.1)
 59 (23.7)
 28 (11.2)
17 (6.8)
15 (6.0)
13 (5.2)
12 (4.8)
12 (4.8)
11 (4.4)
 9 (3.6) 
 6 (2.4)
 3 (1.2)
 4 (1.6)
249
21 (18.4)
33 (28.9)
12 (10.5)
12 (10.5)
7 (6.1)
4 (3.5)
6 (5.2)
6 (5.2)
5 (4.3)
4 (3.5)
2 (1.8)
1 (0.9)
2 (1.8)
114
39 (28.9)
26 (19.2)
16 (11.9)
5 (3.7)
8 (5.9)
9 (6.7)
6 (4.4)
6 (4.4)
6 (4.4)
5 (3.7)
4 (3)
2 (1.5)
2 (1.5)
135
R: Response, N: Non-response.
Chi-Square Tests (df=19, chi-square 19, p=0.612).
Table 5. Summary of logistic regression results*
Variable B S.E. Wald df Significance Exp (B)
Drug-naïve
DOM
DOP
Y-BOCS
Constant
−0.991
−0.092
0.091
0.026
0.695
0.442
0.018
0.021
0.030
0.974
 5.033
26.210
18.575
 0.729
 0.508
1
1
1
1
1
0.025
0.000
0.000
0.393
0.476
0.371
0.912
1.096
1.026
2.003
B: Bonferroni coefficient, S.E.: Standard Error, Wald: Wald statistics, df: degree of freedom, significance: significance of Wald test, Exp(B): 
exponential β (odds ratio), DOM: Duration of medication in YUMC OCD clinic, DOP: Duration of past treatment in other institutes, Y-BOCS: 
Yale-Brown Obsessive-Compulsive Scale. 
*Model Chi-square 51.530, p=0.000, Cox & Snell R2 0.368, Nagelkerke R2 0.458.
Differences Between Responders and Non-Responders 
according to Clinical Subtype of OCD (Table 4)
The total sample of 249 patients included 60 (24.1%) 
participants with the checking subtype of OCD, 59 
(23.7%) with the washing subtype, 28 (11.2%) with the 
pathological doubt subtype, 17 (6.8%) with the symmetry 
and precision subtype, and 15 (6.0%) with the aggressive 
subtype. No significant differences between responders 
and non-responders were observed in terms of subtype. 
Among responders, 33 (28.9%) had the washing subtype, 
21 (18.4%) had the checking subtype, 12 (10.5%) had the 
pathological doubt subtype, and 12 (10.5%) had the sym-
metry and precision subtype. The non-responders group 
included 39 (28.9%) with the checking subtype, 26 
(19.2%) with the washing subtype, 16 (11.9%) with the 
pathological doubt subtype, and 9 (6.7%) with the count-
ing subtype. 
Clinical Predictors of Drug Responses in OCD Patient 
According to the Logistic Regression Analysis (Table 5)
The clinical predictors of drug responses were inves-
tigated using logistic regression to analyze the parameters 
that differentiated between responders and non-respon-
ders. Total baseline scores on the Y-BOCS, duration of re-
ceiving medication at the YUMC OCD clinic, duration of 
previous treatment at other institutions, and status as 
drug-naïve before the study were chosen as independent 
variables, and clinical symptomatology was selected as 
the dependent variable. The analysis showed that the dura-
tion of receiving medication at the YUMC OCD clinic 
was the most significant predictor of drug response and 
that the duration of previous treatment at other in-
stitutions, status as drug-naïve before the study, and total 
baseline scores on the Y-BOS were also significant clin-
ical predictors (Table 5). 
DISCUSSION
This study investigated the major clinical predictors of 
drug responses among OCD patient. For this purpose, we 
examined various parameters that potentially influence 
the treatment of OCD, including the sociodemographic 
characteristics and initial clinical status of patients visiting 
the YUMC OCD clinic. According to this study, the dura-
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tion of pharmacological treatment at the YUMC OCD 
clinic exerted the strongest influence on treatment 
response. Additionally, duration of treatment at other in-
stitutions, prior drug-naïve status, and baseline Y-BOS 
scores were also found to be significant predictors of re-
sponse to medication (Table 2). 
These results may be understood in terms of the time 
needed for medication, education, and other types of treat-
ment to show effectiveness. According to studies con-
ducted by Grimshaw23) and Goodwin et al.24) on the appro-
priate medication duration for OCD patients, most ther-
apeutic effects appear within the first year. Thus, this 
study’s use of 13 months as the average period of ob-
servation was consistent with the other reports.23-25) 
However, additional longer-term research on the im-
portance of medication duration is required because this 
study was limited to an average of only 13 months. 
This study investigated predictors according to the clin-
ical profiles obtained during initial visits to our facility. 
The duration of previous treatment at other institutions, 
previous drug-naïve status, and baseline Y-BOS scores 
were found to be important clinical predictors of medi-
cation response. Given that more responders than non-res-
ponders had been drug-naïve or had received medication 
only briefly in the past, we can hypothesize that in-
appropriate anti-obsessional pharmacotherapy may de-
crease the effect of treatment. That fewer responders ini-
tially reported severe symptoms and that the number of 
responders increased as the duration of pharmacological 
treatment increased indicated that longer periods of medi-
cation are required for patients with more severe ob-
sessive-compulsive symptoms. This finding is consistent 
with the study conducted by de Haan et al.,26) which 
showed that OCD patient with severe symptoms needed 
more medication than did OCD patients with mild 
symptoms.
This study found no relationship between treatment re-
sponse and sex. Because the ratio of male to female partic-
ipants was 180:69, additional research with a more evenly 
divided sample is necessary. Additionally, no significant 
differences in treatment response related to comorbid psy-
chopathology, including the presence of personality dis-
orders, was observed in this study (Table 2). However, the 
finding of significant differences between responders and 
non-responders with respect to the presence of depression 
and obsessive-compulsive personality disorder requires 
further study. 
No significant differences in treatment response ac-
cording to clinical subtype of OCD was observed in this 
study; however, the washing subtype was the most preva-
lent subtype in the responder group, and the checking sub-
type was the most prevalent subtype in the non-responder 
group. No differences in treatment response was observed 
between those with the hoarding and those with the soma-
tization subtypes, which has been suggested as significant 
distinction in terms of predicting treatment response in pa-
tients with OCD.27,28) Additionally, no significant differ-
ences in clinical responses were observed according to 
level of insight or presence of family history of tic 
disorders. 
Thus, the duration of receiving medication at the 
YUMC OCD clinic, the duration of previous treatment at 
other institutions, prior drug-naïve status, and baseline 
Y-BOS scores are the major clinical predictors of re-
sponses to medication among patients with OCD. 
This study has the following limitations. First, no dou-
ble-blind control group was used. Second, because this re-
search was based on a natural follow-up of data obtained 
from patients who visited only the YUMC OCD clinic, 
these results may not be generalizable to all OCD patients. 
Third, patients received various types of medications. 
More accurate clinical results will require the use of a 
standardized treatment protocol. Indeed, a standardized 
medication regimen that is most effective for Korean pa-
tients with OCD needs to be developed by conducting 
comparison studies on treatment with various medica-
tions.
Finally, this study is limited by its inability to study 
long-term treatment effects because, although some pa-
tients were followed for 72 months, the average treatment 
duration was 13 months. Thus, a longer-term follow-up 
study among a consistent group of patients is required. 
Despite these restrictions, this study contributed to the lit-
erature by broadly examining the role of sociodemo-
graphic and clinical factors as predictors of the treatment 
response of patients with OCD and by suggesting areas 
warranting further research in the future. 
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